Heron Therapeutics' stock has significantly declined over the past five years, with shares dropping from over $40 to under $1.20. Despite struggles, the company's recently approved product, ZYNRELEF, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback